Collection

ACMD drug-specific reports

This series brings together all documents relating to ACMD drug-specific reports.

The Advisory Council carries out in-depth reviews of specific drugs, including their classification under the Misuse of Drugs Act 1971.

Documents

  1. Ketamine: rescheduling and patient group directions
  2. Ketamine report
  3. Temporary class drug order on benzofury and NBOMe compounds - letter from ACMD
  4. ACMD advice on tramadol
  5. ACMD advice on independent prescribing of controlled drugs
  6. Khat report 2013
  7. ACMD - Recovery from drug and alcohol dependence: an overview of the evidence (2012)
  8. Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012
  9. Novel psychoactive substances report (2011)
  10. ACMD report on desoxypipradrol
  11. Foil report
  12. Advisory Council on the Misuse of Drugs: Consideration of the anabolic steroids
  13. Advisory Council on the Misuse of Drugs: Consideration of the anabolic steroids
  14. Advisory Council on the Misuse of Drugs Naphyrone Report (2010)
  15. ACMD report on the consideration of the cathinones
  16. ACMD report on the major cannabinoid agonists
  17. ACMD 1-benzylpiperazine (BZP) Report (2008)
  18. MDMA ('ecstasy') review
  19. ACMD report on gamma-butyrolactone (GBL)
  20. ACMD: Cannabis classification and Public Health (2008)
  21. ACMD Drug Facilitated Sexual Assault (DFSA) (2007)
  22. Khat Report 2005
  23. The Advisory Council’s report - Further consideration of the classification of cannabis under the Misuse of Drugs Act 1971 (2005)
  24. ACMD's latest Methylamphetamine Advice
  25. Advisory Council on the Misuse of Drugs Methylamphetamine review 2005 executive summary
  26. Appendix One: Forensic Science Service – Methylamphetamine
  27. The classification of Cannabis under the Misuse of Drugs Act 1971 (2002)
Published 4 June 2013